DelveInsight’s Cutaneous Lupus Erythematosus pipeline report provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
Some of the Key Highlights from the Cutaneous Lupus Erythematosus Pipeline Report
There are currently 15+ drugs in the Cutaneous Lupus Erythematosus pipeline.
The Cutaneous Lupus Erythematosus pipeline consists of therapies in different clinical phase stages, including SAR443122, BMS-986256, CBS004, and others.
Some of the companies actively working to improve the Cutaneous Lupus Erythematosus treatment landscape are Sanofi, Bristol-Myers Squibb, Centessa Pharmaceuticals, HOTH, Biogen, Centessa Pharmaceuticals, Merck, and others.
Denali and Sanofi announced a broad collaboration in October 2018 for the global development and commercialization of RIPK1 inhibitors, including peripherally restricted molecules such as DNL758 and CNS-penetrant molecules such as DNL788 (SAR443820).
CBS004 is being developed and investigated in the preclinical stage by Centessa Pharmaceuticals.
Get a detailed analysis of the pipeline landscape @ Cutaneous Lupus Erythematosus Pipeline Analysis
Cutaneous Lupus Erythematosus: Overview
Cutaneous Lupus Erythematosus (CLE) is an autoimmune disease that can manifest as different skin disease or a systemic lupus erythematosus symptom. Cutaneous lupus erythematosus (LE) can occur as a complication of Systemic Lupus Erythematosus (SLE) or independently of SLE.
Cutaneous Lupus Erythematosus Symptoms
CLE has a broad clinical spectrum, ranging from isolated discoid plaques to widespread skin lesions. Acute cutaneous lupus erythematosus is characterized by transient erythematous patches that occur in conjunction with a flare of systemic lupus erythematosus.
Cutaneous Lupus Erythematosus Treatment
CLE treatment aims to improve skin appearance, limit scarring, and prevent new skin lesions. Sun protection is a critical preventative measure for avoiding skin lupus flares caused by UVB radiation. Pharmacological inhibition of both adaptive and innate immune responses is effective in the treatment of CLE patients. Local therapy, topical steroids, intralesional steroids, systemic therapy, antimalarials, immune modulators such as methotrexate, mycophenolate, dapsone, ciclosporin, and systemic corticosteroids are examples of specific measures.
Cutaneous Lupus Erythematosus Pipeline Analysis: Drug Profiles
SAR443122: Sanofi
Product Description
SAR443122 (DNL758) is a small molecule RIPK1 inhibitor that does not enter the brain. RIPK1 is a tumor necrosis factor (TNF) receptor pathway signaling protein that regulates inflammation and cell death.
Phase II
NCT04781816: Sanofi began a randomized, double-blind, placebo-controlled proof-of-concept study in April 2021 to assess the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chronic cutaneous lupus erythematosus. The primary goal of this study is to determine the efficacy of SAR443122 in patients with cutaneous lupus erythematosus (CLE).
Cutaneous Lupus Erythematosus Pipeline Therapies and Key Companies
BMS-986256: Bristol-Myers Squibb
CBS004: Centessa Pharmaceuticals
Find out the emerging therapies and companies @ Cutaneous Lupus Erythematosus Clinical Trials
Cutaneous Lupus Erythematosus Therapeutics Assessment
By Product Type
Monotherapy
Combination Therapy
By Stage
Discovery
Pre-Clinical
Phase I
Phase III
Pre-registration
By Route of Administration
Inhalation
Intravenous
Oral
Subcutaneous
By Molecule Type
Small Molecule
Stem Cell Therapy
Gene Therapy
Targets
Immune System
Multiple Kinase
By Mechanism of Action
Protease Inhibitors
Immunomodulatory
Scope of the Report
Coverage: Global
Cutaneous Lupus Erythematosus Key Players: Sanofi, Bristol-Myers Squibb, Centessa Pharmaceuticals, HOTH, Biogen, Centessa Pharmaceuticals, Merck, among others
Cutaneous Lupus Erythematosus Pipeline Therapies: SAR443122, BMS-986256, CBS004, and others
Table of Contents
1.
Introduction
2.
Executive Summary
3.
4.
Cutaneous Lupus Erythematosus Pipeline Therapeutics
5.
Cutaneous Lupus Erythematosus Late Stage Products (Pre-registration)
6.
Cutaneous Lupus Erythematosus Late Stage Products (Phase III)
7.
Cutaneous Lupus Erythematosus Mid Stage Products (Phase II)
8.
Cutaneous Lupus Erythematosus Early Stage Products (Phase I)
9.
Cutaneous Lupus Erythematosus Pre-clinical and Discovery Stage Products
10.
11.
Cutaneous Lupus Erythematosus Inactive Products
12.
Cutaneous Lupus Erythematosus- Unmet Needs
13.
Cutaneous Lupus Erythematosus- Market Drivers and Barriers
14.
Appendix
15.
About DelveInsight
Get in touch with our business executive for Healthcare Due Diligence Services
Key questions answered in the Cutaneous Lupus Erythematosus Pipeline Report
What are the treatments for Cutaneous Lupus Erythematosus?
How many pharmaceutical companies are working on treatments for Cutaneous Lupus Erythematosus?
Which of these companies’ pharmaceuticals is the most commonly used?
How many Each company manufactures cutaneous Lupus Erythematosus medications?
How many drugs are in the early, mid, or late stages of development for Cutaneous Lupus Erythematosus?
How many of the currently being developed therapies can be used alone or in combination with other treatments?
What are the essential industry-industry and industry-academy collaborations, mergers and acquisitions, and licensing practices in Cutaneous Lupus Erythematosus?
Related Reports
Systemic Lupus Erythematosus Pipeline Insights
Get a comprehensive analysis of Systemic Lupus Erythematosus pipeline therapies and key companies, including GlaxoSmithKline, AstraZeneca, Biogen, Eli Lilly and Company, Xencor, Pfizer, among others.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/